Mirdametinib with or without radiation for NF1-related high-grade glioma
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a drug called mirdametinib, which targets a protein linked to tumor growth, given alone or with radiation. It is for people with certain brain or spinal cord tumors, especially those with a condition called NF1, to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a high-grade glioma (a fast-growing brain or spinal cord tumor) that is either GBM, IDH-wildtype, or has a TP53 mutation, and it must be linked to NF1 or have an NF1 gene change.
- If you have NF1, you must be at least 12 years old. If you don't have NF1, you must be at least 18.
- You need to have had certain previous treatments (like chemotherapy or radiation) and enough time must have passed since those treatments.
- Your tumor must have certain genetic markers (no IDH, H3, or BRAF mutations).
- You must have adequate organ function (bone marrow, kidneys, liver) and blood pressure within acceptable limits.
- You must not have had certain heart conditions, eye problems, or other serious illnesses that could make the trial unsafe.
- You must agree to use effective birth control if you are fertile, and not donate eggs or sperm during the trial.
- You must have a tissue sample from your tumor available for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
This study tests whether two oral medications (avutometinib and defactinib) are safe and possible to take together with standard radiation therapy in people newly diagnosed with high-grade glioma. It may help control the tumor when used early in treatment.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
This trial tests a study drug called mirdametinib in infants and toddlers who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas (non-cancerous nerve tumors). The study aims to see if the drug can shrink or control these tumors, which may help prevent or reduce symptoms.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
Hear when a new Neurofibromatosis 1 (NF1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.